Although there are studies (Singh et al., 2013; Pinto et al., 2018; Abd El Aziz et al., 2020; Dicembrini et al., 2020; Zhang et al., 2022) on whether DPP-4 inhibitors and GLP-1 analogs increase the risk of pancreatitis, few studies have focused on time to onset. Here, GLP1R is linked to pancreatitis.